{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:04:40Z","timestamp":1773396280628,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ceftazidime-avibactam (CZA), ceftolozane-tazobactam (CT), and imipenem-relebactam (IMR) are newer \u03b2-lactam\/\u03b2-lactamase inhibitor (BL\/BLI) combinations used for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa, although resistance has already emerged. Optimal use of these agents relies on timely, accurate susceptibility testing results and understanding of local resistance mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>183 MDR P. aeruginosa clinical isolates were used to evaluate the performance of commercial Sensititre and Phoenix panels for CZA, CT, and IMR susceptibility testing compared to broth microdilution (BMD). Genomic resistance determinants were also predicted for each isolate with AMRFinderPlus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Categorical agreement (CA) of the Sensititre panel compared to BMD was 95.8%, 90.1%, and 95.8% for CZA, CT, and IMR, respectively. CA of the Phoenix panel was 83.0% for CZA and 85.7% for CT. The Phoenix panel was biased toward under-calling CZA resistance while error rates were acceptable for CT by the error-rate-bound method. AMRFinderPlus identified acquired \u03b2-lactamases in 4.6% of first-time patient isolates. CA of genotype with BMD was 74.9% for CZA, 91.9% for CT, and 90.7% for IMR. However, all agents had unacceptably high VME rates using genotypic testing because many phenotypically resistant isolates had no identifiable genotypic resistance determinants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Sensititre panel met standard acceptance criteria while the Phoenix panel had low CA for all tested BL\/BLIs compared to BMD. Acquired \u03b2-lactamases were a rare cause of BL\/BLI resistance. Further understanding of resistance mechanisms is required before phenotypic BL\/BLI resistance can be reliably predicted from genotype, especially in settings where prevalence of acquired \u03b2-lactamases is low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf585","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:05:28Z","timestamp":1763125528000},"page":"e541-e549","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer \u03b2-lactam\/\u03b2-lactamase Inhibitor Combinations in Multidrug Resistant\n                    <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-3534","authenticated-orcid":false,"given":"Clayton W","family":"Hall","sequence":"first","affiliation":[{"name":"Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-1158","authenticated-orcid":false,"given":"Nicholas","family":"Waglechner","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2104-2256","authenticated-orcid":false,"given":"Erin","family":"Choi","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patryk","family":"Aftanas","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Katz","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]},{"name":"Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre , Toronto, ON ,","place":["Canada"]},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie","family":"Vermeiren","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1203-9514","authenticated-orcid":false,"given":"Finlay","family":"Maguire","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]},{"name":"Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University , Halifax, NS ,","place":["Canada"]},{"name":"Faculty of Computer Science, Dalhousie University , Halifax, NS ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kozak","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]},{"name":"Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre , Toronto, ON ,","place":["Canada"]},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xena X","family":"Li","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, ON ,","place":["Canada"]},{"name":"Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2026031304543677700_jiaf585-B1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026031304543677700_jiaf585-B2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","volume":"31","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026031304543677700_jiaf585-B3","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2026031304543677700_jiaf585-B4","doi-asserted-by":"crossref","first-page":"e01759-19","DOI":"10.1128\/AAC.01759-19","article-title":"Predictors of mortality in bloodstream infections caused by Pseudomonas aeruginosa and impact of antimicrobial resistance and bacterial virulence","volume":"64","author":"Recio","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B5","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00750-12","article-title":"Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia","volume":"56","author":"Morata","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B6","doi-asserted-by":"crossref","first-page":"100940","DOI":"10.1016\/j.lanmic.2024.07.003","article-title":"WHO publishes updated list of bacterial priority pathogens","volume":"5","author":"Jesudason","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026031304543677700_jiaf585-B7","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031304543677700_jiaf585-B8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026031304543677700_jiaf585-B9","doi-asserted-by":"crossref","first-page":"iv32","DOI":"10.1093\/jac\/dkz285","article-title":"Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007\u201316 study","volume":"74","author":"McCracken","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B10","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026031304543677700_jiaf585-B11","doi-asserted-by":"crossref","first-page":"e01117-20","DOI":"10.1128\/AAC.01117-20","article-title":"Mechanisms of resistance to ceftolozane\/tazobactam in pseudomonas aeruginosa: results of the GERPA multicenter study","volume":"65","author":"Fournier","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B12","doi-asserted-by":"crossref","first-page":"e0231224","DOI":"10.1128\/spectrum.02312-24","article-title":"Mutations leading to ceftolozane\/tazobactam and imipenem\/cilastatin\/relebactam resistance during in vivo exposure to ceftazidime\/avibactam in Pseudomonas aeruginosa","volume":"13","author":"Rapsinski","year":"2025","journal-title":"Microbiol Spectr"},{"key":"2026031304543677700_jiaf585-B13","doi-asserted-by":"crossref","first-page":"e0080721","DOI":"10.1128\/jcm.00807-21","article-title":"The ins and outs of susceptibility testing for new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for gram-negative organisms","volume":"60","author":"Dingle","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026031304543677700_jiaf585-B14","volume-title":"CLSI M100 performance standards for antimicrobial susceptibility testing","author":"Clinical Laboratory and Standards Institute","year":"2025","edition":"35th ed"},{"key":"2026031304543677700_jiaf585-B15","volume-title":"CLSI M52 verification of commercial microbial identification and antimicrobial susceptibility testing systems","author":"Clinical Laboratory Standards Institute","year":"2015","edition":"1st ed"},{"key":"2026031304543677700_jiaf585-B16","doi-asserted-by":"crossref","first-page":"e01934-17","DOI":"10.1128\/JCM.01934-17","article-title":"CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2026031304543677700_jiaf585-B17","doi-asserted-by":"crossref","first-page":"e00190-20","DOI":"10.1128\/mSystems.00190-20","article-title":"Bactopia: a flexible pipeline for complete analysis of bacterial genomes","volume":"5","author":"Petit","year":"2020","journal-title":"mSystems"},{"key":"2026031304543677700_jiaf585-B18","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"Fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"2026031304543677700_jiaf585-B19","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.21105\/joss.06830","article-title":"Sourmash v4: a multitool to quickly search, compare, and analyze genomic and metagenomic data sets","volume":"9","author":"Irber","year":"2024","journal-title":"J Open Source Softw"},{"key":"2026031304543677700_jiaf585-B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13059-016-0997-x","article-title":"Mash: fast genome and metagenome distance estimation using MinHash","volume":"17","author":"Ondov","year":"2016","journal-title":"Genome Biol"},{"key":"2026031304543677700_jiaf585-B21","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/bioinformatics\/btu153","article-title":"Prokka: rapid prokaryotic genome annotation","volume":"30","author":"Seemann","year":"2014","journal-title":"Bioinformatics"},{"key":"2026031304543677700_jiaf585-B22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13059-020-02090-4","article-title":"Producing polished prokaryotic pangenomes with the Panaroo pipeline","volume":"21","author":"Tonkin-Hill","year":"2020","journal-title":"Genome Biol"},{"key":"2026031304543677700_jiaf585-B23","doi-asserted-by":"crossref","first-page":"e1004041","DOI":"10.1371\/journal.pcbi.1004041","article-title":"ClonalFrameML: efficient inference of recombination in whole bacterial genomes","volume":"11","author":"Didelot","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"2026031304543677700_jiaf585-B24","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","article-title":"IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era","volume":"37","author":"Minh","year":"2020","journal-title":"Mol Biol Evol"},{"key":"2026031304543677700_jiaf585-B25","doi-asserted-by":"crossref","first-page":"e00483-19","DOI":"10.1128\/AAC.00483-19","article-title":"Validating the AMRFINder tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates","volume":"63","author":"Feldgarden","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B26","doi-asserted-by":"crossref","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"del Barrio-Tofi\u00f1o","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026031304543677700_jiaf585-B27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jac\/dkaa456","article-title":"Activity of imipenem\/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/dkaa396","article-title":"Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane\/tazobactam and ceftazidime\/avibactam during treatment of XDR Pseudomonas aeruginosa infections","volume":"76","author":"Arca-Su\u00e1rez","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B29","doi-asserted-by":"crossref","first-page":"e01375-19","DOI":"10.1128\/AAC.01375-19","article-title":"Acquisition of class C \u03b2-lactamase PAC-1 by sequence type 644 strains of Pseudomonas aeruginosa","volume":"63","author":"Bour","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B30","doi-asserted-by":"crossref","first-page":"e01809-18","DOI":"10.1128\/AAC.01809-18","article-title":"Acquisition of extended-spectrum -lactamase ges-6 leading to resistance to ceftolozane-tazobactam combination in Pseudomonas aeruginosa","volume":"63","author":"Poirel","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jac\/dkac385","article-title":"Phenotypic and genotypic profile of ceftolozane\/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa","volume":"78","author":"Gill","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B32","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B33","doi-asserted-by":"crossref","first-page":"e00894-20","DOI":"10.1128\/AAC.00894-20","article-title":"Adding insult to injury: mechanistic basis for how AmpC mutations allow Pseudomonas aeruginosa to accelerate cephalosporin hydrolysis and evade avibactam","volume":"64","author":"Slater","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B35","doi-asserted-by":"crossref","first-page":"e0206721","DOI":"10.1128\/aac.02067-21","article-title":"Selection of AmpC \u03b2-lactamase variants and metallo\u03b2- lactamases leading to ceftolozane\/tazobactam and ceftazidime\/avibactam resistance during treatment of MDR\/XDR Pseudomonas aeruginosa infections","volume":"66","author":"Ruedas-L\u00f3pez","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B36","doi-asserted-by":"crossref","first-page":"e00084-21","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B37","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B38","doi-asserted-by":"crossref","first-page":"e02085-18","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"key":"2026031304543677700_jiaf585-B39","doi-asserted-by":"crossref","first-page":"e01026-20","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/tazobactam resistance and mechanisms in carbapenem-nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"key":"2026031304543677700_jiaf585-B40","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/jac\/dkad062","article-title":"Simultaneous and divergent evolution of resistance to cephalosporin\/\u03b2-lactamase inhibitor combinations and imipenem\/relebactam following ceftazidime\/avibactam treatment of MDR Pseudomonas aeruginosa infections","volume":"78","author":"Alonso-Garc\u00eda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","volume":"80","author":"Shah","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026031304543677700_jiaf585-B42","doi-asserted-by":"crossref","first-page":"e0067024","DOI":"10.1128\/aac.00670-24","article-title":"Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021","volume":"68","author":"Li","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031304543677700_jiaf585-B43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/cid\/ciac097","article-title":"Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia","volume":"75","author":"Shields","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031304543677700_jiaf585-B44","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","article-title":"In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa","volume":"75","author":"Gomis-Font","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031304543677700_jiaf585-B45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026031304543677700_jiaf585-B46","doi-asserted-by":"crossref","first-page":"e0319624","DOI":"10.1128\/spectrum.03196-24","article-title":"Diagnostic algorithm for the detection of carbapenemases and extended-spectrum \u03b2-lactamases in carbapenem-resistant Pseudomonas aeruginosa","volume":"13","author":"Mancini","year":"2025","journal-title":"Microbiol Spectr"},{"key":"2026031304543677700_jiaf585-B47","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.cmi.2021.05.011","article-title":"Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis","volume":"27","author":"Cortes-Lara","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026031304543677700_jiaf585-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-024-01346-z","article-title":"Keeping up with the pathogens: improved antimicrobial resistance detection and prediction from Pseudomonas aeruginosa genomes","volume":"16","author":"Madden","year":"2024","journal-title":"Genome Med"},{"key":"2026031304543677700_jiaf585-B49","doi-asserted-by":"crossref","first-page":"1335096","DOI":"10.3389\/fcimb.2024.1335096","article-title":"Genomic and phenotypic inconsistencies in Pseudomonas aeruginosa resistome among intensive care patients","volume":"14","author":"Dolgusevs","year":"2024","journal-title":"Front Cell Infect Microbiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf585\/65359964\/jiaf585.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/e541\/65359964\/jiaf585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/e541\/65359964\/jiaf585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:56:35Z","timestamp":1773392195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/2\/e541\/8325550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,17]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf585","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,11,17]]}}}